• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
#

Medicines

: 7
Wizz Air withheld 2027 guidance due to uncertainty around the Iran conflict / Photo: Toni. M / Shutterstock.com
Small Caps·13.06.2026 16:01
Small caps last week: Record biotech IPO, Wizz Air's solid top line, SpaceX effect
  • ZEAL.CO
  • ZEAL
  • WIZZ.L
  • PBLS
Shares of Zealand Pharma plummeted as much as 25% after new data on an experimental weight loss medicine raised concerns over its side effects / Photo: MAXSHOT.PL / Shutterstock
Small Caps·08.06.2026 17:49
Small weight loss drugmaker Zealand sinks as new safety data spooks investors
  • ZEAL
  • ZEAL.CO
Lilly and Novo simultaneously filed applications for approval of new obesity drugs
News·19.12.2025 15:21
Lilly and Novo simultaneously filed applications for approval of new obesity drugs
  • LLY
  • NOVO-B.CO
Medline shares soared 41% after this years biggest IPO. Should you buy them?
News·18.12.2025 15:41
Medline shares soared 41% after this year's biggest IPO. Should you buy them?
  • MDLN
Biggest IPO of the year: shares of medical products giant Medline become available
News·17.12.2025 15:00
Biggest IPO of the year: shares of medical products giant Medline become available
  • MDLN
Moderna and Novavax shares fall amid reports of 10 likely deaths after vaccination
News·01.12.2025 22:47
Moderna and Novavax shares fall amid reports of 10 likely deaths after vaccination
  • MRNA
  • NVAX
  • PFE
The U.S. Department of Health is preparing a report on the risks of taking Tylenol. Shares of the manufacturer collapsed
News·06.09.2025 03:15
The U.S. Department of Health is preparing a report on the risks of taking Tylenol. Shares of the manufacturer collapsed
  • KVUE
X-channel

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026